1. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). (October 2018) Authors: van Rossum, A.G.J.; Kok, M.; van Werkhoven, E.; Opdam, M.; Mandjes, I.A.M.; van Leeuwen – Stok, A.E.; van Tinteren, H.; Imholz, A.L.T.; Portielje, J.E.A.; Bos, M.M.E.M.; van Bochove, A.; Wesseling, J.; Rutgers, E.J.; Linn, S.C.; Oosterkamp, H.M. Journal: European journal of cancer Issue: Volume 102(2018) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗